The positive hBD3 expression rates were 23% (5/22) in normal cervix, 90% (37/41) in cancer in situ, and 94% (35/37) in cervical cancers (Figure 1B, p<0.01) (Figure 1B). Here, DEFB103A is linked to cervical cancer.